Biden s vaccine booster and export plans to collide at summit news24.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news24.com Daily Mail and Mail on Sunday newspapers.
Sheryl Gay Stolberg and Sharon LaFraniere, The New York Times Published: 13 Jul 2021 08:51 AM BdST Updated: 13 Jul 2021 08:51 AM BdST A tray contains Pfizer-BioNTech COVID-19 vaccines at a vaccination event in Miami on May 17, 2021. The New York Times
Representatives of Pfizer met privately with senior US scientists and regulators Monday to press their case for swift authorisation of coronavirus booster vaccines, amid growing public confusion about whether they will be needed and pushback from federal health officials who say the extra doses are not necessary now. ); }
The high-level online meeting, which lasted an hour and involved Pfizer’s chief scientific officer briefing virtually every top doctor in the federal government, came on the same day Israel started administering third doses of the Pfizer-BioNTech vaccine to heart transplant patients and others with compromised immune systems. Officials said after the m
BioVaxys reçoit une réponse positive de la FDA pour l évaluation préalable à la PNMR du développement clinique du programme CoviDTH prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
April 14, 2021
Reuters
CHICAGO/LONDON - With two Covid-19 vaccines now under scrutiny for possible links to very rare cases of blood clots in the brain, US government scientists are focusing on whether the specific technology behind the shots may be contributing to the risk.
In Europe, health regulators said last week there was a possible link between the AstraZeneca Plc vaccine and 169 cases of a rare brain blood clot known as cerebral venous sinus thrombosis (CVST), accompanied by a low blood platelet count, out of 34 million shots administered in the European Economic Area.
The US Food and Drug Administration on Tuesday (April 13) recommended temporarily halting use of the Johnson & Johnson vaccine after reports of six cases of CVST in women under age 50 among some 7 million people who received the shot in the United States.